Cardio-Protective Effect of Saxagliptin and Dapagliflozin Combination on Endothelial Progenitor Cells in Patients with Type 2 Diabetes

We are looking if Saxagliptin and Dapagliflozin, which are FDA approved Diabetes medications, will improve your cardiovascular health. We are looking for patients who are between 30-70 years of age with HbA1c from 7 to 10%, who are taking Metformin and/or Insulin only for their Diabetes.

Astra Zeneca Pharmaceuticals, LP
Principal Investigator(s)
Saby Sen, MD, PhD
Contact Phone Number
Request Information

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

7 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.